JP2015529657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529657A5 JP2015529657A5 JP2015525760A JP2015525760A JP2015529657A5 JP 2015529657 A5 JP2015529657 A5 JP 2015529657A5 JP 2015525760 A JP2015525760 A JP 2015525760A JP 2015525760 A JP2015525760 A JP 2015525760A JP 2015529657 A5 JP2015529657 A5 JP 2015529657A5
- Authority
- JP
- Japan
- Prior art keywords
- conditions
- cancer
- diseases
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 241000222722 Leishmania <genus> Species 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000011149 active material Substances 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12005716 | 2012-08-07 | ||
| EP12005716.1 | 2012-08-07 | ||
| PCT/EP2013/002032 WO2014023385A1 (en) | 2012-08-07 | 2013-07-10 | Pyridopyrimidine derivatives as protein kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076582A Division JP2018150307A (ja) | 2012-08-07 | 2018-04-12 | プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015529657A JP2015529657A (ja) | 2015-10-08 |
| JP2015529657A5 true JP2015529657A5 (enExample) | 2017-09-28 |
| JP6374384B2 JP6374384B2 (ja) | 2018-08-15 |
Family
ID=48782275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525760A Expired - Fee Related JP6374384B2 (ja) | 2012-08-07 | 2013-07-10 | プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体 |
| JP2018076582A Pending JP2018150307A (ja) | 2012-08-07 | 2018-04-12 | プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076582A Pending JP2018150307A (ja) | 2012-08-07 | 2018-04-12 | プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9725462B2 (enExample) |
| EP (1) | EP2882746B1 (enExample) |
| JP (2) | JP6374384B2 (enExample) |
| CN (1) | CN104507942B (enExample) |
| AR (1) | AR092365A1 (enExample) |
| AU (1) | AU2013301865B2 (enExample) |
| CA (1) | CA2881279C (enExample) |
| ES (1) | ES2618004T3 (enExample) |
| IL (1) | IL237073A (enExample) |
| WO (1) | WO2014023385A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014010176A (es) * | 2012-02-23 | 2014-11-10 | Abbvie Inc | Inhibidores de cinasas de piridopirimidinona. |
| CN104507942B (zh) * | 2012-08-07 | 2017-03-22 | 默克专利股份公司 | 作为蛋白质激酶抑制剂的吡啶并嘧啶衍生物 |
| KR20140027714A (ko) * | 2012-08-27 | 2014-03-07 | 주식회사 홍인터내셔날 | 외부 디바이스와 연동하는 다트 게임 장치 |
| KR102591886B1 (ko) | 2015-07-21 | 2023-10-20 | 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. | 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용 |
| CN116478132A (zh) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
| ES2881395T3 (es) | 2016-12-22 | 2021-11-29 | Calithera Biosciences Inc | Composiciones y métodos para inhibir la actividad de la arginasa |
| CN110446709B (zh) * | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| AU2018210196B2 (en) | 2017-01-23 | 2022-06-02 | Revolution Medicines, Inc. | Pyridine compounds as allosteric SHP2 inhibitors |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| AU2018301837A1 (en) * | 2017-07-13 | 2020-02-06 | Syros Pharmaceuticals, Inc. | Tam kinase inhibitors |
| WO2019051291A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| CA3078565A1 (en) | 2017-10-12 | 2019-04-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| WO2019100106A1 (en) * | 2017-11-24 | 2019-05-31 | The University Of Sydney | Antibacterial compounds and methods of use thereof |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| JP7266043B2 (ja) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| JP6995025B2 (ja) | 2018-08-09 | 2022-02-04 | 株式会社豊田自動織機 | 太陽熱集熱管 |
| CN110833557A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗肾小管肾炎的用途 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| NZ782284A (en) | 2019-05-21 | 2024-11-29 | Amgen Inc | Solid state forms |
| US20230002414A1 (en) * | 2019-08-22 | 2023-01-05 | Blueray Therapeutics (Shanghai) Co., Ltd | Azaheteroaryl compound and application thereof |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| US11534441B2 (en) * | 2020-01-15 | 2022-12-27 | Blueprint Medicines Corporation | MAP4K1 inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230143059A1 (en) * | 2020-02-17 | 2023-05-11 | Alesta Therapeutics BV | Gcn2 modulator compounds |
| WO2022048684A1 (zh) * | 2020-09-07 | 2022-03-10 | 武汉朗来科技发展有限公司 | Jnk抑制剂、其药物组合物和用途 |
| WO2022079250A1 (en) | 2020-10-16 | 2022-04-21 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| EP4228632A4 (en) * | 2020-10-16 | 2025-02-19 | Saint Louis University | Rev-erb agonists |
| CN121057726A (zh) * | 2023-05-31 | 2025-12-02 | 西湖制药(杭州)有限公司 | 一种病毒蛋白酶抑制剂的结晶及用途 |
| CN117180122B (zh) * | 2023-11-02 | 2024-04-09 | 杭州湃肽生化科技有限公司 | 一种舒敏修复组合物及其应用 |
| WO2025240517A1 (en) * | 2024-05-14 | 2025-11-20 | Aleksia Therapeutics, Inc. | Cdk4 inhibitor naphthyridine compounds |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959368A (en) * | 1986-02-24 | 1990-09-25 | Mitsui Petrochemical Industries Ltd. | Therapeutic agent for neurological diseases |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| CZ200331A3 (cs) | 2000-07-07 | 2003-04-16 | Angiogene Pharmaceuticals Limited | Deriváty kolchinolu jako inhibitory angiogeneze, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
| JP5802127B2 (ja) | 2008-04-16 | 2015-10-28 | ポートラ ファーマシューティカルズ， インコーポレイテッド | Ｓｙｋ又はｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド類 |
| CA2723135A1 (en) | 2008-05-01 | 2009-11-05 | Sirtris Pharmaceuticals, Inc. | Quenolines and related analogs as sirtuin modulators |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| EP2352732B1 (en) | 2008-12-01 | 2013-02-20 | Merck Patent GmbH | 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER |
| EP2493313B1 (en) | 2009-10-29 | 2017-12-13 | Genosco | Kinase inhibitors |
| CA2784830C (en) | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN104507942B (zh) * | 2012-08-07 | 2017-03-22 | 默克专利股份公司 | 作为蛋白质激酶抑制剂的吡啶并嘧啶衍生物 |
-
2013
- 2013-07-10 CN CN201380041839.3A patent/CN104507942B/zh not_active Expired - Fee Related
- 2013-07-10 EP EP13735205.0A patent/EP2882746B1/en active Active
- 2013-07-10 WO PCT/EP2013/002032 patent/WO2014023385A1/en not_active Ceased
- 2013-07-10 ES ES13735205.0T patent/ES2618004T3/es active Active
- 2013-07-10 JP JP2015525760A patent/JP6374384B2/ja not_active Expired - Fee Related
- 2013-07-10 AU AU2013301865A patent/AU2013301865B2/en not_active Ceased
- 2013-07-10 CA CA2881279A patent/CA2881279C/en active Active
- 2013-07-10 US US14/420,003 patent/US9725462B2/en not_active Expired - Fee Related
- 2013-08-07 AR ARP130102804A patent/AR092365A1/es unknown
-
2015
- 2015-02-03 IL IL237073A patent/IL237073A/en active IP Right Grant
-
2018
- 2018-04-12 JP JP2018076582A patent/JP2018150307A/ja active Pending